Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Edwards Lifesciences Corp    EW

Delayed Quote. Delayed  - 12/09 10:02:31 pm
90.37 USD   +1.20%
12/09 EDWARDS LIFESCI : Unveils Structural Heart Pipeline
12/08 S&P 500 MOVERS : Hrb, ew
12/08 EDWARDS LIFESCI : Outlines Growth Strategy At Annual Investor Confer..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Edwards Lifesciences Corp : Edwards Lifesciences to Host Earnings Conference Call on April 24, 2012

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/16/2012 | 10:28pm CET

IRVINE, CA, April 16, 2012

To participate in the conference call, dial (877) 407-8037 or (201) 689-8037. For 72 hours following the call, an audio replay can be accessed by dialing (877) 660-6853 or (201) 612-7415 and using account number 2995 and conference number 392053. The call will also be available via live or archived webcast on the "Investor Relations" section of the Edwards web site at www.edwards.com or http://www.edwards.com/InvestorRelations/EventCalendar.htm.

About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. Additional company information can be found at www.edwards.com.

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.

# # #
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EDWARDS LIFESCIENCES CORP
12/09 EDWARDS LIFESCIENCES : Unveils Structural Heart Pipeline
12/08 VALTECH : Cardio, Ltd. Agrees to be Acquired by Edwards Lifesciences
12/08 EDWARDS LIFESCIENCES : Patent Issued for Surgical Heart Valves Identifiable Post..
12/08 S&P 500 MOVERS : Hrb, ew
12/08 EDWARDS LIFESCIENCES : Outlines Growth Strategy At Annual Investor Conference
12/07 EDWARDS LIFESCIENCES : Assigned Patent
12/02 FRIDAY 12/2 INSIDER BUYING REPORT : Ew, dfrg
11/30 EDWARDS LIFESCIENCES : U.S. Patents Awarded to Inventors in Utah (Nov. 30)
11/29 EDWARDS LIFESCIENCES CORP : Blog Coverage Edwards Lifesciences Acquires Valtech;..
11/28 EDWARDS LIFESCIENCES : Israeli Valtech Cardio acquired by Edwards Lifesciences i..
More news
Sector news : Advanced Medical Equipment & Technology - NEC
12/08 AIXTRON : China's Fujian drops Aixtron bid after Obama blocks deal
12/05 Aixtron could revive takeover despite U.S. block
12/02 Deals scuppered by U.S. regulatory scrutiny
11/29 European spin-offs and carve-outs
11/15 EXCLUSIVE : EU regulators seen clearing $25 billion Abbott, St Jude deal
More sector news : Advanced Medical Equipment & Technology - NEC
News from SeekingAlpha
12/08 Neovasc Soars As Mitral Valves Head To Europe
12/08 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
12/08 Edwards Lifesciences sees 2017 top-line up as much as 14% with non-GAAP EPS o..
12/08 Large-cap stocks with the most upside next year, according to sell-side
12/06 Wait On Twilio - Cramer's Lightning Round (12/05/16)
Advertisement
Financials ($)
Sales 2016 2 959 M
EBIT 2016 817 M
Net income 2016 593 M
Finance 2016 704 M
Yield 2016 -
P/E ratio 2016 33,40
P/E ratio 2017 26,77
EV / Sales 2016 6,29x
EV / Sales 2017 5,59x
Capitalization 19 322 M
More Financials
Chart EDWARDS LIFESCIENCES CORP
Duration : Period :
Edwards Lifesciences Corp Technical Analysis Chart | EW | US28176E1082 | 4-Traders
Full-screen chart
Technical analysis trends EDWARDS LIFESCIEN...
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 116 $
Spread / Average Target 29%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Stanton J. Rowe Chief Scientific Officer & VP-Advanced Technology
John P. McGrath Vice President-Quality, Regulatory & Clinical
John T. Cardis Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
EDWARDS LIFESCIENCES C..13.07%19 322
THERMO FISHER SCIENTIF..2.51%57 441
DANAHER CORPORATION9.50%54 022
BOSTON SCIENTIFIC CORP..11.77%28 336
PHILIPS18.95%28 064
INTUITIVE SURGICAL, IN..13.42%24 225
More Results